卡泊三醇0.005%与二丙酸倍他米松0.064%固定剂量复方凝胶治疗青少年头皮及躯体银屑病的II期试验
这项II期研究评估了卡泊三醇/倍他米松复方凝胶在12至<17岁青少年银屑病患者中的安全性和疗效,患者每日一次外用不超过8周。107例患者中7例(7%)出现药物不良反应,最常见不良事件为头痛、鼻咽炎和血甲状旁腺激素升高,各6例(6%)、6例(6%)和4例(4%)。治疗结束时,58%的患者躯体皮损达到PGA控制,69%头皮皮损达到控制。
要点
- 青少年轻中度银屑病可用卡泊三醇/倍他米松复方凝胶每日一次,疗程≤8周。
- 药物不良反应发生率7%,常见不良事件为头痛、鼻咽炎和甲状旁腺激素升高。
- 治疗终点躯体PGA控制率58%,头皮控制率69%。
核心结论
- 在无对照的II期研究中,卡泊三醇/倍他米松复方凝胶治疗青少年头皮和躯体银屑病耐受性良好且有效。
研究设计与样本
- II期、无对照研究,纳入12至<17岁、躯体和头皮至少轻度银屑病的青少年患者。
- 患者接受卡泊三醇(0.005%)/倍他米松(0.064%以二丙酸酯计)复方凝胶每日一次外用,疗程≤8周。
- 共107例患者入组并接受治疗,中位年龄14岁(范围12-16岁)。
主要发现
- 7例(7%)患者出现8次药物不良反应,38例(36%)患者发生至少1次不良事件。
- 最常见不良事件为头痛6例(6%)、鼻咽炎6例(6%)、血甲状旁腺激素升高4例(4%)。
- 报告1例严重不良事件(自杀未遂),判定与治疗无关。
- 治疗结束时,根据PGA,58%的患者躯体银屑病达到控制,69%的患者头皮银屑病达到控制。
关键数值与推荐
- 安全主要终点为药物不良反应(研究者判定可能与或很可能与治疗相关的不良事件)。
- 疗效终点为PGA评估的疾病控制。
临床怎么用
- 对于12至<17岁头皮和躯体银屑病青少年,可考虑使用卡泊三醇/倍他米松复方凝胶每日一次,疗程不超过8周。
- 治疗期间需关注头痛、鼻咽炎及血甲状旁腺激素升高等潜在不良事件。
局限性
- 本研究为无对照II期研究,缺乏对照组,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis is a disease that commonly manifests in adolescence. Up to half of adults with psoriasis develop it before the age of 20. Topical formulations containing corticosteroids and/or vitamin D3 analogs are recommended for treatment. OBJECTIVE: This phase II study aimed to evaluate the safety, including any potential effect on the hypothalamic-pituitary-adrenal axis and calcium metabolism, and efficacy of fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) (Cal/BD) gel in adolescents with psoriasis. METHODS: Patients aged 12 to <17 years, with at least mild psoriasis on the body and scalp, received topical Cal/BD gel once daily for ≤8 weeks. Safety response criteria included adverse drug reactions [ADRs; any adverse event (AE) possibly or probably related to treatment as determined by the investigator; a primary response criterion] and AEs (a secondary response criterion). Only treatment-emergent AEs (events that occurred after the first application of Cal/BD gel or events which started before this and increased in intensity after the first application of Cal/BD gel) are presented here. Efficacy response criteria included controlled disease, by physician's global assessment of disease severity (PGA), following Cal/BD gel treatment. RESULTS: A total of 107 patients (median age 14 years; range 12-16) were enrolled and treated. Eight ADRs were observed in 7 (7%) patients and 38 (36%) patients experienced ≥1 AE. The most common AEs were headache [6 (6%) patients], nasopharyngitis [6 (6%) patients] and blood parathyroid hormone increased [4 (4%) patients]. One severe AE was reported (attempted suicide) but was considered unrelated to treatment. At the end of treatment, 58% of patients had controlled disease on the body and 69% on the scalp according to PGA. CONCLUSION: In this uncontrolled phase II study, Cal/BD gel was well tolerated and effective for treating scalp and body psoriasis in adolescents.
引用
- Eichenfield LF, Marcoux D, Kurvits M, et al. Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial. J Eur Acad Dermatol Venereol. 2020. PMID: 31721327. doi:10.1111/jdv.16077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。